Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Cash from Operations (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Cash from Operations for 4 consecutive years, with 16101000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 33.53% to 16101000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 103900000.0 through Dec 2025, up 5.66% year-over-year, with the annual reading at 103900000.0 for FY2025, 5.66% up from the prior year.
  • Cash from Operations for Q4 2025 was 16101000.0 at Century Therapeutics, up from 25584000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 86753000.0 in Q1 2022, with the low at 34623000.0 in Q1 2025.
  • Average Cash from Operations over 4 years is 18020687.5, with a median of 25570000.0 recorded in 2022.
  • Peak annual rise in Cash from Operations hit 43.69% in 2023, while the deepest fall reached 133.68% in 2023.
  • Over 4 years, Cash from Operations stood at 22907000.0 in 2022, then fell by 14.51% to 26230000.0 in 2023, then grew by 7.65% to 24223000.0 in 2024, then skyrocketed by 33.53% to 16101000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 16101000.0, 25584000.0, and 27592000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.